bpc-157 risks studies BPC-157: Tendon Repair and More bpc-157 human studies dosing safety

Appetite and food reward 3-arm Phase 1 tirzepatide vs liraglutide 3.0 mg vs placebo: measured lunch intake fell 524.6 kcal vs placebo by week 3 (about 72% by week 6), with craving and hedonic-hunger reductions exceeding liraglutide

Some research supports oral use of BPC-157, especially for gut healing applicationswhich makes sense given that it's derived from a gastric protein

[298] The stratification of results by age and mental health diagnosis, as well as standardization of measure performance scores by volume, is sufficient to account for differences between hospitals without further need for risk adjustment

Perhaps intestinal barrier damage may be linked to the development of hypertension [89,90,91]